Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Crizotinib
108
CHF
CHF 108.00
In stock
CDX-C0699-M01010 mgCHF 108.00
CDX-C0699-M05050 mgCHF 326.00
| Product Details | |
|---|---|
| Synonyms | (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine; PF 2341066; PF-02341066; PF02341066; Xalkori |
| Product Type | Chemical |
| Properties | |
| Formula | C21H22Cl2FN5O |
| MW | 450.34 |
| CAS | 877399-52-5 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white powder. |
| Solubility | Soluble in choroform, DMSO or methanol. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | KTEIFNKAUNYNJU-GFCCVEGCSA-N |
| Smiles | NC1=NC=C(C2=CN(C3CCNCC3)N=C2)C=C1O[C@H](C)C4=C(Cl)C(F)=CC=C4Cl |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +20°C |
| Long Term Storage | +4°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at +4°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Crizotinib is an anticancer drug. It is a potent, orally bioavailable, ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor), anaplastic lymphoma kinase (ALK) and ROS1 (c-ros oncogene 1). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable. Crizotinib was approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.
Product References
(1) H.Y. Zou, et al.; Cancer Res. 67, 4408 (2007) | (2) J.G. Christensen, et al.; Mol. Cancer Ther. 6, 3314 (2007) | (3) J.J. Cui, et al.; J. Med. Chem. 54, 6342 (2011) | (4) J. Tanizaki, et al.; J. Thorac. Oncol. 6, 1624 (2011) | (5) Y. Yuan, et al.; J. Hematol. Oncol. 4, 1 (2011) | (6) A.T. Shaw, et al.; N. Engl. J. Med. 371, 1963 (2014)